Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MyoVera
- Development stage
- Unknown
- Lead developer
- EverWell
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MyoVera is a patented dietary supplement ingredient developed by Nutrition21 for muscle health and strength optimization. It is a proprietary combination of amylopectin and a chromium complex, designed to be used in conjunction with protein supplementation and exercise. The ingredient works by amplifying muscle protein synthesis (MPS) and supporting the uptake of amino acids into muscle tissue, thereby maximizing the body's utilization of protein for muscle growth and repair. Formerly marketed as Velositol, MyoVera is intended for use in various product formats, including powders, beverages, and nutrition bars, to support lean muscle mass development.
- Brand names
- MyoVeraVelositol
- Other names
- amylopectin + chromium complex
02
Targets
Beyond the preview
Go deeper on MyoVera.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MyoVera.